Clinical Trial Update: A Phase 1b Study of SGN-75 in Combination With Everolimus in Patients With Renal Cell Carcinoma [Phase 1]

View source ↗

Summary

This is a Phase 1b study evaluating SGN-75 in combination with everolimus for renal cell carcinoma, which has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Everolimus (everolimus)
• SGN-75

Snippet

Sponsor: Seagen Inc. | Conditions: Renal Cell Carcinoma | Phase 1 | Status: TERMINATED